https://www.patientcareonline.com/view/donanemab-kisunla-authorized-in-europe-for-early-symptomatic-alzheimer-disease
Donanemab (Kisunla) Authorized in Europe for Early Symptomatic Alzheimer Disease | Patient Care...
Oct 16, 2026 - The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.
in europealzheimer diseasepatient caredonanemabkisunla
https://alzheimersweekly.com/massive-investment-in-alzheimers-drug-kisunla/
Massive Investment in Alzheimer's Drug Kisunla
Sep 16, 2024 - Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer's. New investment will enhance global medicine production, benefiting...
massiveinvestmentalzheimerdrugkisunla